<DOC>
	<DOC>NCT01663415</DOC>
	<brief_summary>The purpose of this study is to investigate radiographic progression-free survival (PFS) of enzalutamide in chemotherapy-naïve patients with progressive metastatic castration-resistant prostate cancer who have symptomatic disease.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Progressive prostate cancer while on androgen deprivation therapy Castrate testosterone level Maintenance of surgical or medical castration for duration of study Radiographically visible metastatic disease Symptomatic from prostate cancer Eastern Cooperative Oncology Group (ECOG) 02 Life expectancy &gt;=6 months Brain metastases or leptomeningeal disease Prior cytotoxic chemotherapy for prostate cancer Prior use of ketoconazole or abiraterone acetate or other investigational agent that blocks androgen synthesis or targets androgen receptor History of seizure or condition that may predispose to seizure History of loss of consciousness or transient ischemic attack within 12 months Clinically significant cardiovascular disease</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>MDV3100</keyword>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>enzalutamide</keyword>
</DOC>